Develops therapeutics to extend human healthspan by slowing, halting, or reversing age-related diseases.
Unity Biotechnology, Inc. is a pioneering biotechnology firm dedicated to advancing therapies aimed at mitigating, stopping, or reversing age-related diseases. Established in 2009 and headquartered in South San Francisco, California, the company focuses on groundbreaking research and development in the field of aging-related ailments. Originally known as Forge, Inc., Unity Biotechnology, Inc. rebranded in January 2015, marking a strategic shift towards specializing in the biology of aging.
Unity Biotechnology, Inc. is at the forefront of developing innovative treatments designed to combat various age-related conditions. Its diverse pipeline includes promising candidates such as UBX1325, currently in Phase II clinical trials for diabetic macular edema and other age-related eye diseases. Additionally, the company is advancing UBX1967 for ophthalmologic disorders, UBX2050, a monoclonal antibody targeting age-related eye ailments, and UBX2089, a potential treatment for multiple neurology indications.
The company's research efforts are driven by a commitment to leveraging cutting-edge biotechnological insights to address the complex challenges of aging. Unity Biotechnology, Inc.'s comprehensive approach aims to provide therapeutic solutions that enhance quality of life and extend healthy lifespan, reinforcing its position as a leader in the burgeoning field of longevity science.